Advaccine Biopharma Suzhou and Sinovac Biotech will conduct two China trials of Sinovac's approved COVID-19 vaccine combined with US-based Innovio's DNA vaccine candidate for COVID-19. Earlier this year, Advaccine announced a $108 million agreement to acquire China rights to the Innovio vaccine. In animal testing, the combination of INO-4800 and Sinovac's CoronaVac, an attenuated vaccine, produced a higher response against the virus. Advaccine is sponsoring the trial. More details.... Stock Symbol: (NSDQ: INO) Share this with colleagues: // //